- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03614260
El estudio fundamental RADIANCE II: un estudio del sistema ReCor Medical Paradise en la etapa II de la hipertensión (RADIANCE-II)
The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at the time of consent. Prior to randomization, subjects will be hypertensive in the absence of hypertension medication.
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Erlangen, Alemania, D-91054
- University Clinic Erlangen
-
Homburg, Alemania, D-66421
- University Clinic of Saarland - Homburg
-
Karlsruhe, Alemania, 76133
- Klinikum Karlsruhe GmbH
-
Konstanz, Alemania, D-78464
- Klinikum Konstanz
-
Leipzig, Alemania, D-04289
- Herzzentrum Leipzig GmbH
-
Lübeck, Alemania, D-23560
- Sana Kliniken Lübeck GmbH
-
-
-
-
-
Brussels, Bélgica, 1000
- Centre Hospitalier Universitaire Saint-Pierre
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35211
- Cardiology PC
-
-
California
-
Los Angeles, California, Estados Unidos, 940048
- Cedars Sinai Medical Center
-
-
Connecticut
-
Bridgeport, Connecticut, Estados Unidos, 06610
- Bridgeport Hospital
-
Stamford, Connecticut, Estados Unidos, 06904
- Stamford Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20010
- MedStar Washington
-
-
Florida
-
Gainsville, Florida, Estados Unidos, 32605
- The Cardiac and Vascular Institute
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30308
- Emory University Hospital Midtown
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Northwestern University
-
Springfield, Illinois, Estados Unidos, 62794
- Southern Illinois University
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70121
- Ochsner Heart and Vascular Institute
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02120
- The Brigham and Women's Hospital
-
-
Michigan
-
Traverse City, Michigan, Estados Unidos, 49684
- Munson Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55407
- Minneapolis Heart Institute Foundation
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64111
- Saint Luke's Health System
-
-
Nevada
-
Reno, Nevada, Estados Unidos, 89502
- Renown Regional Medical Center
-
-
New Jersey
-
Browns Mills, New Jersey, Estados Unidos, 08015
- Deborah Heart & Lung Center
-
Hackensack, New Jersey, Estados Unidos, 07601
- Hackensack University
-
-
New York
-
New York, New York, Estados Unidos, 10032
- Columbia University Medical Center/NYPH
-
New York, New York, Estados Unidos, 10075
- Northwell Health Inc.
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27599
- The University of North Carolina at Chapel Hill
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44195
- Cleveland Clinic
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- University of Pennsylvania Health System
-
Pittsburgh, Pennsylvania, Estados Unidos, 15213
- University of Pittsburgh Medical Center
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29425
- Medical University of South Carolina
-
-
Tennessee
-
Memphis, Tennessee, Estados Unidos, 38163
- The University of Tennessee Health Science Center
-
Nashville, Tennessee, Estados Unidos, 37232
- Vanderbilt University
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84132
- University of Utah
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98122
- Swedish Medical Center
-
-
-
-
-
Bordeaux, Francia, 33000
- Hôpital Saint André
-
Lille, Francia, 59000
- CHRU de Lille
-
Paris, Francia, 75015
- Hôpital Européen Georges-Pompidou (HEGP)
-
-
-
-
-
Galway, Irlanda, H91 YR71
- University Hospital Galway
-
-
-
-
-
Rotterdam, Países Bajos, 3015 GD
- Erasmus Medical Center
-
-
-
-
-
Bournemouth, Reino Unido, BH7 7DW
- University Hospitals Dorset NHS Foundation Trust
-
Canterbury, Reino Unido, CT1 3NG
- Kent & Canterbury Hospital
-
Cardiff, Reino Unido
- University Hospital Wales
-
London, Reino Unido, EC1A 7BE
- St Bartholomew's Hospital
-
Newcastle upon Tyne, Reino Unido, NE7 7DN
- Freeman Hospital
-
-
Essex
-
Basildon, Essex, Reino Unido, SS16 5NL
- The Cardiothoracic Centre Basildon University Hospital
-
-
-
-
-
Geneva, Suiza, 1211
- Hôpitaux Universitaires Genève
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Previously or currently prescribed antihypertensive therapy
- Average office BP ≥ 140/90 mmHg <180/120 mmHg while stable for at least 4 weeks on 0-2 classes of antihypertensive medication
- Documented daytime ABP ≥ 135/85 mmHg and < 170/105 mmHg after 4-week washout/run-in period
Exclusion Criteria:
- Lacks appropriate renal artery anatomy for treatment
- Known, uncorrected causes of secondary hypertension other than sleep apnea
- Type I diabetes mellitus or uncontrolled Type II diabetes
- eGFR of <40
- Brachial circumference ≥ 42 cm
- Any history of cerebrovascular event or severe cardiovascular event, or history of stable or unstable angina within 12 months prior to consent
- Repeat (>1) hospitalization for hypertensive crisis within 12 months prior to screening period, or any hospitalization for hypertensive crisis within 3 months prior to screening period
- Chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea
- Primary pulmonary hypertension
- Night shift workers
- Pregnant, nursing or planning to become pregnant
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Renal Denervation
Renal Angiogram and Renal Denervation (Paradise Renal Denervation System) |
Following renal angiogram according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
Otros nombres:
|
|
Comparador falso: Sham Control
Renal Angiogram |
Following renal angiogram to standard procedures, subjects remain blinded and renal angiogram is considered the sham procedure. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Average Daytime Ambulatory Systolic BP
Periodo de tiempo: From baseline to 2 months post-procedure
|
The primary efficacy outcome is the mean change in daytime ambulatory systolic blood pressure at 2 months |
From baseline to 2 months post-procedure
|
|
Percentage of Participants With Major Adverse Events (MAE)
Periodo de tiempo: From baseline to 30 days post-procedure
|
The primary safety composite outcome of major adverse events included death, kidney failure, and major embolic, vascular, cardiovascular, cerebrovascular, and hypertensive events at 30 days. |
From baseline to 30 days post-procedure
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Average 24-hr Ambulatory Systolic BP
Periodo de tiempo: From baseline to 2 months post-procedure
|
Change in average 24-hr ambulatory systolic blood pressure |
From baseline to 2 months post-procedure
|
|
Change in Average Office Systolic BP
Periodo de tiempo: From baseline to 2 months post-procedure
|
Change in average office systolic blood pressure |
From baseline to 2 months post-procedure
|
|
Change in Average Home Systolic BP
Periodo de tiempo: From baseline to 2 months post-procedure
|
Change in average home systolic blood pressure |
From baseline to 2 months post-procedure
|
|
Change in Average Daytime Ambulatory Diastolic BP
Periodo de tiempo: From baseline to 2 months post-procedure
|
Change in average daytime ambulatory diastolic blood pressure |
From baseline to 2 months post-procedure
|
|
Change in Average 24-hr Ambulatory Diastolic BP
Periodo de tiempo: From baseline to 2 months post-procedure
|
Change in average 24-hr ambulatory diastolic blood pressure |
From baseline to 2 months post-procedure
|
|
Change in Average Office Diastolic BP
Periodo de tiempo: From baseline to 2 months post-procedure
|
Change in average office diastolic blood pressure |
From baseline to 2 months post-procedure
|
|
Change in Average Home Diastolic BP
Periodo de tiempo: From baseline to 2 months post-procedure
|
Change in average home diastolic blood pressure |
From baseline to 2 months post-procedure
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Ajay Kirtane, MD, SM, Columbia University Medical Center/New York-Presbyterian Hospital and the Cardiovascular Research Foundation
- Investigador principal: Prof. Michel Azizi, MD, PhD, Professor of Vascular Medicine, Hypertension Dept. and Clinical Investigation Center, Hôpital Européen Georges Pompidou
Publicaciones y enlaces útiles
Publicaciones Generales
- Azizi M, Saxena M, Wang Y, Jenkins JS, Devireddy C, Rader F, Fisher NDL, Schmieder RE, Mahfoud F, Lindsey J, Sanghvi K, Todoran TM, Pacella J, Flack J, Daemen J, Sharp ASP, Lurz P, Bloch MJ, Weber MA, Lobo MD, Basile J, Claude L, Reeve-Stoffer H, McClure CK, Kirtane AJ; RADIANCE II Investigators and Collaborators. Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial. JAMA. 2023 Feb 28;329(8):651-661. doi: 10.1001/jama.2023.0713.
- Azizi M, Sharp ASP, Fisher NDL, Weber MA, Lobo MD, Daemen J, Lurz P, Mahfoud F, Schmieder RE, Basile J, Bloch MJ, Saxena M, Wang Y, Sanghvi K, Jenkins JS, Devireddy C, Rader F, Gosse P, Claude L, Augustin DA, McClure CK, Kirtane AJ; RADIANCE Investigators. Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program. Circulation. 2024 Mar 5;149(10):747-759. doi: 10.1161/CIRCULATIONAHA.123.066941. Epub 2023 Oct 26.
- Kirtane AJ, Sharp ASP, Mahfoud F, Fisher NDL, Schmieder RE, Daemen J, Lobo MD, Lurz P, Basile J, Bloch MJ, Weber MA, Saxena M, Wang Y, Sanghvi K, Jenkins JS, Devireddy C, Rader F, Gosse P, Sapoval M, Barman NC, Claude L, Augustin D, Thackeray L, Mullin CM, Azizi M; RADIANCE Investigators and Collaborators. Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials. JAMA Cardiol. 2023 May 1;8(5):464-473. doi: 10.1001/jamacardio.2023.0338.
- Bytyqi V, Kannenkeril D, Striepe K, Bosch A, Karg MV, Schmid A, Schiffer M, Uder M, Schmieder RE. Predicting blood pressure response to renal denervation based on a new approach. J Hypertens. 2025 Mar 1;43(3):413-419. doi: 10.1097/HJH.0000000000003918. Epub 2024 Oct 29.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- RADIANCE II Study
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .